Neurol. pro Praxi, 2003; 2: 79-82

Syndrom neklidných končetin v neurologické praxi

MUDr. Martin Pretl CSc
Neurologická klinika 1. LF UK a VFN, Praha

Keywords: syndrom neklidných končetin, patofyziologie, diagnostika, terapie.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pretl M. Syndrom neklidných končetin v neurologické praxi. Neurol. praxi. 2003;4(2):79-82.

Syndrom neklidných končetin (RLS - restless legs syndrome) je definován 4 základními diagnostickými kritérii: (1) nepříjemnými pocity v končetinách (dysestézie), které vyvolávají (2) motorický neklid a nutkavý pocit k pohybu, (3) maximum obtíží se vyskytuje v klidu, (4) večer a časně v noci. Patofyziologickým podkladem se zdá být dysfunkce v oblasti dopaminergního systému. K diagnóze postačuje dobrá anamnéza, eventuálně polysomnografické vyšetření či aktigrafie. Léčba spočívá v podávání L-Dopy, agonistů dopaminu či opioidů.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/ levodopa. Sleep 1996; 19: 205-213. Go to original source... Go to PubMed...
    2. Collado-Seidel V, Kohnen R, Samtleben W, Hillebrand GF, Oertel WH, Trenkwalder C. Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis 1998; 31: 324-328. Go to original source... Go to PubMed...
    3. Desautels A, Turecki G, Montplaisir J, Brisebois K, Sequeira A, Adam B et al. Evidence for a genetic association between monoamine oxidase A and restless legs syndrome. Neurology 2002; 59: 215-219. Go to original source... Go to PubMed...
    4. Ekbom K. Restless legs: a clinical study. Acta Med Scand Suppl 1945; 158: 1-123.
    5. Entezari-Taher M, Singleton JR, Jones CR, Meekins G, Petajan JH, Smith AG. Changes in excitability of motor cortical circuitry in primary restless legs syndrome. Neurology 1999; 53: 1201-1205. Go to original source... Go to PubMed...
    6. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002; 59: 1573-1579. Go to original source... Go to PubMed...
    7. Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993; 43: 445. Go to original source... Go to PubMed...
    8. Hening WA. Restless legs syndrome: a sensimotor dysorder of sleep/wake motor regulation. Curr Neurol Neurosci Rep 2002; 2: 186-196 Go to original source... Go to PubMed...
    9. Hertz G, Fast A, Feinsilver SH, Albertario CL, Schulman H, Fein AM. Sleep in normal late pregnancy. Sleep 1992; 15: 246-251. Go to original source... Go to PubMed...
    10. Johnson E. Omnibus sleep in America Poll. Washington: National Sleep Foundation; 2001: 46s.
    11. Kavey N, Walters AS, Hening W, Gidro-Frank S. Opioid treatment of periodic movements in sleep in patients without restless legs. Neuropeptides. 1998; 11: 181-184. Go to original source... Go to PubMed...
    12. Kock N, Culjkovic B. Mode of Inheritance and Susceptibility Locus for Restless Legs Syndrome on Chromosome 12q. Am J Hum Genet 2002; 71: 205-208. Go to original source... Go to PubMed...
    13. Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry 1999; 60: 241-244. Go to original source... Go to PubMed...
    14. Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000; 160: 2137-2141. Go to original source... Go to PubMed...
    15. Saletu M, Anderer P, Saletu-Zyhlarz G, Prause W, Semler B, Zoghlami A, Gruber G, Hauer C, Saletu B. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepame. Eur Neuropsychopharmacol. 2001; 11: 153-161. Go to original source... Go to PubMed...
    16. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep 1998; 21: 371-377. Go to original source... Go to PubMed...
    17. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999; 52: 932-937. Go to original source... Go to PubMed...
    18. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of Restless Legs Syndrome among males aged 18-64 ys. An association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001; 16: 1159-1163. Go to original source... Go to PubMed...
    19. Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, Kavey N. Succesfull treatment of the idiopatic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993; 16: 327-332. Go to original source... Go to PubMed...
    20. Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995; 10: 634-642. Go to original source... Go to PubMed...
    21. Willis T. The London practice of physick. London: Bassett, Dring, Harper, and Crook; 1692.
    22. Zucconi M, Coccagna G, Petronelli R, Gerardi R, Mondini S, Cirignotta F. Nocturnal myoclonus in restless legs syndrome effect of carbamazepine treatment. Funct Neurol. 1989; 4: 263-271.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.